Search company, investor...

Primorigen Biosciences


Acquired | Acquired

Total Raised


About Primorigen Biosciences

Primorigen develops, produces and aims to provide technical support for cell therapy research products, including well characterized antibodies, protein targets and microarrays to characterize the developmental state of a cell.

Headquarters Location

510 Charmany Drive

Madison, Wisconsin, 53719,

United States


Missing: Primorigen Biosciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Primorigen Biosciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Primorigen Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Primorigen Biosciences is included in 2 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Primorigen Biosciences Patents

Primorigen Biosciences has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Stem cells, Developmental biology, Clusters of differentiation, Biotechnology


Application Date


Grant Date



Related Topics

Transcription factors, Stem cells, Developmental biology, Clusters of differentiation, Biotechnology



Latest Primorigen Biosciences News

Nucleus Biologics acquires Primorigen Biosciences, gains proprietary, high yield, recombinant...

Aug 6, 2019

Nucleus Biologics now has the leading xeno-free, recombinant, extracellular matrix News provided by Share this article SAN DIEGO, Aug. 6, 2019 /PRNewswire/ -- Nucleus Biologics, a leader in precision cell culture, is pleased to announce the acquisition of Primorigen Biosciences, Inc. The addition of Primorigen's Vitronectin XF™ and platform recombinant protein production technology will play a huge role in Nucleus' strategy of offering traceable, reproducible and xeno-free (XF) cell culture ecosystems for the cell and gene therapy space. When growing human cells for cell and gene therapy, XF products provide a physiologically relevant environment that has no animal derived components. Vitronectin XF™  is a recombinant extracellular matrix (ECM) that promotes cell proliferation, maintains pluripotency and supports normal colony morphology, for mesenchymal and induced pluripotent stem cells. Vitronectin XF™ is one of the leading ECMs on the market and is human cell derived, full length, fully glycosylated and completely xeno-free. Vitronectin XF™ is sold around the world direct and through distributors. "We are excited to build on the work of the Primorigen team and support our new customers, distributors and suppliers," said David Sheehan, Founder, President and CEO of Nucleus Biologics. "This product is a foundation stone for a novel pipeline of products that include cGMP Vitronectin XF™, Vitronectin XF™ Microcarriers and other recombinant proteins to be used in our complete media products. If we truly want to speed science, we will need to provide complete, characterized and disclosed ecosystems. "   Chuck Oehler, CEO of Primorigen, stated, "The exceptionally strong fit of the Nucleus and Primorigen product portfolios provide a compelling value proposition for customers seeking more complete solutions for cell biology research and production." About Nucleus Biologics Nucleus Biologics is a San Diego based biotechnology company and a global provider of media and supplements for the cell and gene therapy space. Their mission is to speed the time from scientific discovery to cure by driving reproducibility through Precision Cell Culture products and tools. Nucleus Biologics delivers innovative, transparent and cGMP products and services with the goal of disrupting the market and eliminating antiquated practices and products. Ultimately, Nucleus Biologics strives to create a new paradigm that serves both scientists and clinicians, while reducing the environmental footprint of cell culture. About Primorigen Biosciences Primorigen Biosciences, Inc., a Madison, WI based biotechnology company is a research and manufacturing company that has a proprietary process for producing high quality full length recombinant human proteins cost effectively. Primorigen's versatile coated microcarrier platform provided superior cell proliferation and seeding efficiency in customer trials while reducing preparation from multiple days to minutes. Media Contact:

Primorigen Biosciences Frequently Asked Questions (FAQ)

  • Where is Primorigen Biosciences's headquarters?

    Primorigen Biosciences's headquarters is located at 510 Charmany Drive, Madison.

  • What is Primorigen Biosciences's latest funding round?

    Primorigen Biosciences's latest funding round is Acquired.

  • How much did Primorigen Biosciences raise?

    Primorigen Biosciences raised a total of $2.45M.

  • Who are the investors of Primorigen Biosciences?

    Investors of Primorigen Biosciences include Nucleus Biologics, Louisiana Emerging Technology Center and Louisiana Funds.

  • Who are Primorigen Biosciences's competitors?

    Competitors of Primorigen Biosciences include ViaCyte, Guava Technologies, Sequenom, BioSilta, Cellumen and 11 more.

Compare Primorigen Biosciences to Competitors


CellCura, Inc. is a company dedicated to the development of equipment and products for use in assisted reproductive technology (ART) and stem cell research.


IntelCell markets a product platform engineered to modernize research techniques for cell and tissue growth. The company's first product, Cell Drive, replaces traditional cell culture equipment by providing an unprecedented level of usability and sophistication for the user. For scientists whose research depends upon live cell culture, Cell Drive aims to offer a compact, precision, cell growth system that increases experimental control, aims to improve sterility, aims to provide digitization of data and methods, and aims to reduce human error and labor costs.

Plectix Biosystems

Plectix BioSystems Inc. is focussed on approaches for overcoming challenges faced by biologists in the complex world of cell signaling.

DC Biosciences Logo
DC Biosciences

DC Biosciences, formerly Dundee Cell Products, provides pharmaceutical and biotech companies with novel technologies and proteomics services to accelerate the development of safer drugs.

CellAura Technologies

CellAura Technologies is a spin out company from the University of Nottingham, combining world-renowned expertise in the fields of synthetic chemistry and molecular pharmacology to produce high quality fluoresent G-protein coupled receptor ligands for use in molecular pharmacology and imaging at the single cell level.


BioSilta, founded in 2007 in Oulu, Finland, utilizes its unique, proprietary EnBase technology platform to develop innovative, reagent-based EnPresso growth systems. When compared to conventional growth media, these growth systems significantly increase the yield of high quality biomolecules from microbial cultures.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.